title: Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy.
authors.affiliation: POLIKUM Friedenau Berlin, POLIKUM MVZ GmbH, Rubensstraβe 119, 12157 Berlin, Germany.
authors.forename: Wolf Peter
authors.initials: WP
authors.lastname: Hofmann
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
mesh_terms: D000998:Antiviral Agents; D000075202:Contraindications; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012367:RNA, Viral / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D059039:Standard of Care
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; C100416:peginterferon alfa-2a